Een trial naar het effect van influenzavaccinatie bij ouderen: Ethisch, uitvoerbaar en hard nodig

Miquel B. Ekkelenkamp; C. H. Van Werkhoven; Patricia C.J. Bruijning-Verhagen; Marc J.M. Bonten

Een trial naar het effect van influenzavaccinatie bij ouderen: Ethisch, uitvoerbaar en hard nodig

Translated title of the contribution: A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed

Miquel B. Ekkelenkamp, C. H. Van Werkhoven^*, Patricia C.J. Bruijning-Verhagen, Marc J.M. Bonten

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.

Translated title of the contribution	A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed
Original language	Dutch
Article number	D3285
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	162
Issue number	38
Publication status	Published - 1 Jan 2018

Cite this

@article{60fabef3407a49728bc8b354bb0260a3,

title = "Een trial naar het effect van influenzavaccinatie bij ouderen: Ethisch, uitvoerbaar en hard nodig",

abstract = "Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.",

author = "Ekkelenkamp, {Miquel B.} and {Van Werkhoven}, {C. H.} and Bruijning-Verhagen, {Patricia C.J.} and Bonten, {Marc J.M.}",

year = "2018",

month = jan,

day = "1",

language = "Dutch",

volume = "162",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu van Loghum",

number = "38",

}

TY - JOUR

T1 - Een trial naar het effect van influenzavaccinatie bij ouderen

T2 - Ethisch, uitvoerbaar en hard nodig

AU - Ekkelenkamp, Miquel B.

AU - Van Werkhoven, C. H.

AU - Bruijning-Verhagen, Patricia C.J.

AU - Bonten, Marc J.M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.

AB - Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.

UR - http://www.scopus.com/inward/record.url?scp=85053818061&partnerID=8YFLogxK

M3 - Article

C2 - 30306759

AN - SCOPUS:85053818061

SN - 0028-2162

VL - 162

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 38

M1 - D3285

ER -

Een trial naar het effect van influenzavaccinatie bij ouderen: Ethisch, uitvoerbaar en hard nodig

Abstract

Other files and links

Fingerprint

Cite this